China
# |
Name |
Revenue Per Share |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 107.02
|
March 31, 2024 | USD 1.94 | -1.52% |
|
China |
|
2 |
USD 26.96
|
Dec. 31, 2023 | USD 2.59 | 1.33% |
|
China |
|
3 |
USD 19.08
|
Dec. 31, 2023 | USD 3.66 | 2.21% |
|
China |
|
4 |
USD 17.33
|
Dec. 31, 2023 | USD 4.77 | 5.76% |
|
China |
|
5 |
USD 14.53
|
Dec. 31, 2023 | USD 1.68 | 2.25% |
|
China |
|
6 |
USD 10.07
|
Dec. 31, 2023 | USD 1.40 | 3.01% |
|
China |
|
7 |
USD 9.91
|
Dec. 31, 2023 | USD 1.58 | 1.46% |
|
China |
|
8 |
USD 9.28
|
Dec. 31, 2023 | USD 4.26 | 1.90% |
|
China |
|
9 |
USD 8.31
|
Dec. 31, 2023 | USD 2.85 | 3.99% |
|
China |
|
10 |
USD 8.11
|
Dec. 31, 2023 | USD 2.34 | 2.64% |
|
China |
|
11 |
USD 7.46
|
Dec. 31, 2023 | USD 1.80 | 2.86% |
|
China |
|
12 |
USD 7.39
|
Dec. 31, 2023 | USD 6.55 | -6.69% |
|
China |
|
13 |
USD 7.23
|
Dec. 31, 2023 | USD 1.10 | 2.94% |
|
China |
|
14 |
USD 6.55
|
Dec. 31, 2023 | USD 0.70 | 2.41% |
|
China |
|
15 |
USD 6.54
|
Dec. 31, 2023 | USD 2.27 | 3.13% |
|
China |
|
16 |
USD 6.17
|
Dec. 31, 2023 | USD 4.23 | 5.08% |
|
China |
|
17 |
USD 5.84
|
Dec. 31, 2023 | USD 0.65 | 2.15% |
|
China |
|
18 |
USD 5.74
|
Dec. 31, 2023 | USD 1.24 | -0.08% |
|
China |
|
19 |
USD 5.41
|
Dec. 31, 2023 | USD 0.67 | 1.67% |
|
China |
|
20 |
USD 5.12
|
Dec. 31, 2023 | USD 12.91 | 2.15% |
|
China |
|
21 |
USD 4.16
|
Dec. 31, 2023 | USD 2.19 | 4.03% |
|
China |
|
22 |
USD 4.08
|
Dec. 31, 2023 | USD 1.67 | 2.01% |
|
China |
|
23 |
USD 4.06
|
Dec. 31, 2023 | USD 32.18 | 1.97% |
|
China |
|
24 |
USD 4.00
|
Dec. 31, 2023 | USD 7.41 | 1.09% |
|
China |
|
25 |
USD 3.96
|
Dec. 31, 2023 | USD 3.00 | 0.74% |
|
China |
|
26 |
USD 3.88
|
Dec. 31, 2023 | USD 5.83 | 2.79% |
|
China |
|
27 |
USD 3.66
|
Dec. 31, 2023 | USD 1.47 | 2.19% |
|
China |
|
28 |
USD 3.41
|
Dec. 31, 2023 | USD 0.53 | 1.44% |
|
China |
|
29 |
USD 3.25
|
Dec. 31, 2023 | USD 4.53 | 2.64% |
|
China |
|
30 |
USD 3.16
|
Dec. 31, 2023 | USD 0.46 | 3.40% |
|
China |
|
31 |
USD 3.16
|
Dec. 31, 2023 | USD 3.33 | 0.92% |
|
China |
|
32 |
USD 3.11
|
Dec. 31, 2023 | USD 3.45 | 3.36% |
|
China |
|
33 |
USD 3.08
|
Dec. 31, 2023 | USD 7.83 | 2.23% |
|
China |
|
34 |
USD 3.05
|
Dec. 31, 2023 | USD 1.93 | 2.10% |
|
China |
|
35 |
USD 3.05
|
Dec. 31, 2023 | USD 1.46 | 3.48% |
|
China |
|
36 |
USD 3.04
|
Dec. 31, 2023 | USD 10.09 | 5.71% |
|
China |
|
37 |
USD 3.01
|
Dec. 31, 2023 | USD 1.50 | 1.37% |
|
China |
|
38 |
USD 2.92
|
Dec. 31, 2023 | USD 1.34 | 1.74% |
|
China |
|
39 |
USD 2.80
|
Dec. 31, 2023 | USD 3.43 | 3.12% |
|
China |
|
40 |
USD 2.76
|
Dec. 31, 2023 | USD 2.49 | 0.18% |
|
China |
|
41 |
USD 2.72
|
Dec. 31, 2023 | USD 5.92 | 1.98% |
|
China |
|
42 |
USD 2.58
|
Dec. 31, 2023 | USD 3.54 | 2.01% |
|
China |
|
43 |
USD 2.52
|
Dec. 31, 2023 | USD 0.99 | 4.49% |
|
China |
|
44 |
USD 2.41
|
Dec. 31, 2023 | USD 48.02 | 4.49% |
|
China |
|
45 |
USD 2.39
|
Dec. 31, 2023 | USD 3.65 | 3.06% |
|
China |
|
46 |
USD 2.37
|
Dec. 31, 2023 | USD 2.19 | 2.04% |
|
China |
|
47 |
USD 2.35
|
Dec. 31, 2023 | USD 28.52 | 2.04% |
|
China |
|
48 |
USD 2.22
|
Dec. 31, 2023 | USD 2.05 | 4.96% |
|
China |
|
49 |
USD 2.17
|
Dec. 31, 2023 | USD 1.71 | 1.65% |
|
China |
|
50 |
USD 2.17
|
Dec. 31, 2023 | USD 2.86 | 2.75% |
|
China |
The Health Care company in China with the highest Revenue Per Share is China Jo-Jo Drugstores, Inc. (NasdaqCM: CJJD) at USD 107.02.
The Health Care company in China with the lowest Revenue Per Share is Connect Biopharma Holdings Limited (NasdaqGM: CNTB) at USD 0.00.
The top 10 Health Care companies in China by Revenue Per Share are China Jo-Jo Drugstores, Inc., Sinopharm Group Co. Ltd., China National Accord Medicines Corporation Ltd., Concord Medical Services Holdings Limited, Cachet Pharmaceutical Co., Ltd., Zhejiang Int'l Group Co.,Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, China National Medicines Corporation Ltd., Yunnan Jianzhijia Health-Chain Co., Ltd. and Guangxi LiuYao Group Co., Ltd.
The bottom 10 Health Care companies in China by Revenue Per Share are Connect Biopharma Holdings Limited, Shanghai Bio-heart Biological Technology Co., Ltd., HighTide Therapeutics Inc, Genor Biopharma Holdings Limited, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Abbisko Cayman Limited, Zhaoke Ophthalmology Limited, Ascletis Pharma Inc., Jiangsu Recbio Technology Co., Ltd. and Wuhan YZY Biopharma Co Ltd.